过氧化物还原酶2及其潜在的临床应用价值研究进展被引量：3

Research Progress of Peroxiredoxin 2 and Its Potential in Clinical Applications

导出

摘要过氧化物还原酶2(peroxiredoxins,Prx2)是过氧化物还原酶家族的重要一员,在人体多种组织器官中都有表达,红细胞内含量极其丰富。Prx2在清除过氧化物、信号转导、分子伴侣等方面发挥着重要作用。Prx2结构和表达量的改变与多种疾病直接相关,是临床诊断及药物开发领域的新关注点。本文从Prx2的生理功能及其与不同疾病的相关性、不同存在形式、Prx2的检测手段3个方面进行综述,为进一步探究Prx2与疾病调控机制及其在疾病诊断和潜在临床应用的研究方面提供参考。 Peroxiredoxin 2（Prx2） is an important member of peroxiredoxin family. It is widely distributed in various tissues and organs of human body, especially abundant in erythrocytes. Prx2 can function as a scavenger of peroxide, sensor and transducer of cell signals, molecular chaperone and so on. Changes in the structure and expression of Prx2 are related to many human diseases, consequently making Prx2 a new focus in clinical diagnosis and drug development. This review generally introduced the physiological functions of Prx2 and its relation with different human diseases, as well as detecting techniques of Prx2 in different forms. It aims to study the regulation mechanism of Prx2 and its potential in disease diagnosis and other clinical applications.

作者王丽敏杜诗琦王佳凤李博狄斌 WANG Limin;DU Shiqi;WANG Jiafeng;LI Bo;DI Bin(Department of Pharmaceutical Analysis,Key Laboratory on Protein Chemistry and Structural Biology,MOE Key Laboratory of Drug Quality Control and Pharmacovigilance,China Pharmaceutical University,Nanjing 210009,China)

机构地区中国药科大学药物分析系蛋白质化学与结构生物学重点实验室药物质量与安全预警教育部重点实验室

出处《中国现代应用药学》 CAS CSCD 北大核心 2018年第10期1573-1579,共7页 Chinese Journal of Modern Applied Pharmacy

基金中央高校基本科研业务费专项资金资助(2632017ZD07)

关键词过氧化物还原酶2 生理功能检测方法临床应用 peroxiredoxin 2 physiological functions detecting techniques clinical applications

分类号 R969.3 [医药卫生—药理学]

引文网络
相关文献

参考文献1

1王丽丽,石磊,袁平,徐成伟,李召东.雷洛昔芬对慢性低氧大鼠肺动脉血管重构的作用[J].中国现代应用药学,2015,32(6):681-685. 被引量：3

二级参考文献14

1HOEPER M M, BARBERA J A, CHANNICK R N, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension [J]. J Am Coil Cardiol, 2009, 54(3): 85-96.
2SIMONNEAU G, ROBBINS I M, BEGHETTI M, et al. Updated clinical classification of pulmonary hypertension [J]. J Am Coil Cardiol, 2009, 54(3): 43-54.
3STENMARK K R, MEYRICK B, GALIE N, et al. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure [J]. Am J Physiol Lung Cell Mol Physiol, 2009, 297(5): 1013-1032.
4LAHM T, PATEL K M, CRISOSTOMO P R, et al. Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: The effects of sex and menstrual cycle [J]. Am J Physiol Endocrinol Metab, 2007, 293(4): 865-871.
5YUAN P, WU W H, GAO L, et al. Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, PGI2 and ET- 1 pathway [J]. Eur Respir 1, 2013.41 (5): 1116-1125.
6LAHM T, ALBRECHT M, FISHER A J, et al. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects [J]. Am J Respir Crit Care Med, 2012, 185(4): 965-980.
7YUAN P, L1U D, ZHANG R, et al. Estrogen and pulmonary hypertension [J]. 中华医学杂志, 2009, 89(3): 3448-3450.
8SAKAO S, TATSUMI K, VOELKEL N F. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation [J]. Respir Res, 2009, 10(2) 95-96.
9RABINOVITCH M. Molecular path genesis of pulmonary arterial hypertension [J]. J Clin Invest, 2008, 118(6): 2372 -2379.
10LIU J Q, FOLZ R J. Extracellular superoxide enhances 5-HT-induced murine pulmonary artery vasoconstriction [J]. Am J Physiol Lung Cell Mol Physiol, 2004, 287(5): 111-118.